fenfluramine has been researched along with Pulmonary Hypertension in 116 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of pulmonary hypertension presenting with sudden cardiac arrest, hyperthyroidism and fenfluramine usage." | 8.83 | Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review. ( Chan, CK; Leung, YY; Tang, KS; Tsang, CC; Wong, KK; Yu, AW, 2006) |
| "Fenfluramine derivatives (Fds) are a well-established risk factor for primary pulmonary hypertension (PPH)." | 8.80 | Primary pulmonary hypertension associated with the use of fenfluramine derivatives. ( Fartoukh, M; Hervé, P; Humbert, M; Jagot, JL; Simonneau, G; Sitbon, O, 1998) |
| "Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug." | 8.80 | Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. ( Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR, 1998) |
| "Reports dealing with long-term effects of fenfluramines on brain serotonin neurons, body weight, and pulmonary function in animals and humans." | 8.79 | Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. ( McCann, UD; Ricaurte, GA; Rubin, LJ; Seiden, LS, 1997) |
| "Obesity is a chronic condition that is accompanied by a number of metabolic complications." | 7.78 | Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. ( Davis, R; Faulds, D, 1996) |
| "To test whether the clinical presentation and prognosis of fenfluramine-induced pulmonary hypertension (PH) differs from primary PH (PPH), we compared the clinical profile and outcome of 10 patients with fenfluramine-induced PH with that of 70 patients with PPH referred to our center over the same time frame and treated identically." | 7.72 | Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. ( McLaughlin, V; Rich, S; Shillington, A, 2003) |
| "Appetite-suppressant drug fenfluramine is implicated in primary pulmonary hypertension (PPH) but the molecular pathways that mediate this effect are unknown." | 7.72 | Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. ( Abramowicz, MJ; Blanpain, C; Detheux, M; Knoop, C; Le Poul, E; Parma, J; Parmentier, M; Vassart, G, 2003) |
| "This study investigated whether patients developing pulmonary arterial hypertension (PAH) after exposure to the appetite suppressants fenfluramine and dexfenfluramine have mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene, as reported in primary pulmonary hypertension." | 7.71 | BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. ( Barst, RJ; Cuervo, N; Deng, Z; Hodge, SE; Humbert, M; Knowles, JA; Moore, KJ; Morse, JH; Simonneau, G; Sitbon, O; Wolf, M, 2002) |
| "5) received fenfluramine and phentermine (fen-phen) for 7 months, and pulmonary hypertension subsequently developed." | 7.71 | Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. ( Tomita, T; Zhao, Q, 2002) |
| "The anorexiant dexfenfluramine, which inhibits 5-hydroxytryptamine (5-HT) uptake, has been associated with an increase in the relative risk of developing primary pulmonary hypertension." | 7.70 | Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. ( Adnot, S; Eddahibi, S; Launay, JM; Raffestin, B; Sitbon, M, 1998) |
| "In the late 1960s, an epidemic of primary pulmonary hypertension (PPH) occurred in Europe shortly after the introduction of aminorex fumarate, a potent anorexigen." | 7.70 | Aminorex, dexfenfluramine, and primary pulmonary hypertension. ( Kramer, MS; Lane, DA, 1998) |
| "Dexfenfluramine and fenfluramine greatly increase the risk of developing pulmonary hypertension (PHT)." | 7.70 | Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. ( Archer, SL; Dall'ava-Santucci, J; Dinh-Xuan, AT; Djaballah, K; Fartoukh, M; Humbert, M; Mercier, JC; Simonneau, G; Weir, KE, 1998) |
| "Anorectic agents, such as aminorex and fenfluramine derivatives, have been associated previously with the development of primary pulmonary hypertension." | 7.70 | Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. ( Fedullo, P; Masliah, E; Strother, J; Yi, ES, 1999) |
| "The authors report a case of severe pulmonary hypertension after long-term dexfenfluramine treatment in a 48 year old man with no previous medical history." | 7.69 | [Severe pulmonary hypertension complicating a long treatment with dexfenfluramine]. ( Baudouy, M; Drai, E; Ferrari, E; Jourdan, J; Morand, P; Sanchez, B, 1994) |
| "Pulmonary hypertension was diagnosed in a 41-year-old woman after 16 months' use of fenfluramine as a treatment for obesity." | 7.69 | [Pulmonary hypertension following use of fenfluramine for obesity]. ( Maesen, BL; Snijder, RJ; Stricker, BH, 1994) |
| "There has been suggestion of a possible relationship between the intake of the appetite suppressant dexfenfluramine and the development of primary pulmonary hypertension." | 7.69 | Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. ( Delcroix, M; Leeman, M; Maggiorini, M; Naeije, R; Wauthy, P, 1995) |
| "Appetite suppressants, including aminorex and fenfluramine, have been associated with pulmonary hypertension ever since the well-known outbreak of primary pulmonary hypertension in Europe after treatment with aminorex." | 7.69 | Pulmonary hypertension and dexfenfluramine. ( Cacoub, P; Dorent, R; Gandjbakhch, I; Godeau, P; Houppe, JP; Nataf, P; Piette, JC, 1995) |
| "Fenfluramine is a widely prescribed anorectic drug as adjuvant therapy for obesity." | 7.68 | Pulmonary hypertension and fenfluramine. ( Cheriex, EC; Pouwels, HM; Smeets, JL; Wouters, EF, 1990) |
| "Pulmonary hypertension developed in two women who had been taking fenfluramine for over eight months for weight reduction." | 7.66 | Pulmonary hypertension and fenfluramine. ( Douglas, JG; Kitchin, AH; Muir, AL; Munro, JF; Proudfoot, AT, 1981) |
| "Benfluorex is a fenfluramine derivative which has been marketed between 1976 and 2009." | 5.46 | Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report. ( Banfi, C; Baufreton, C; Bruneval, P; Ennezat, PV; Fouquet, O; Giraud, R; Rousselet, MC, 2017) |
| "Benfluorex was marketed in France until 2009, despite its similar pharmacological properties with fenfluramine and its derivatives known to be a cause of pulmonary arterial hypertension (PAH)." | 5.38 | Pulmonary hypertension associated with benfluorex exposure. ( Bergot, E; Bourdin, A; Chaumais, MC; Cottin, V; Dromer, C; Frachon, I; Habib, G; Humbert, M; Jaïs, X; Lamblin, N; Montani, D; Pison, C; Poubeau, P; Prevot, G; Reynaud-Gaubert, M; Sanchez, O; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P, 2012) |
| "We report a case of pulmonary hypertension presenting with sudden cardiac arrest, hyperthyroidism and fenfluramine usage." | 4.83 | Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review. ( Chan, CK; Leung, YY; Tang, KS; Tsang, CC; Wong, KK; Yu, AW, 2006) |
| " The use of aminorex, an amphetamine analog that increases norepinephrine levels in the central nervous system, led to an epidemic of primary pulmonary hypertension (PPH) in Europe in the late 1960s and early 1970s." | 4.81 | Anorectic drugs and pulmonary hypertension from the bedside to the bench. ( Michelakis, ED; Weir, EK, 2001) |
| "Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug." | 4.80 | Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. ( Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR, 1998) |
| "Fenfluramine derivatives (Fds) are a well-established risk factor for primary pulmonary hypertension (PPH)." | 4.80 | Primary pulmonary hypertension associated with the use of fenfluramine derivatives. ( Fartoukh, M; Hervé, P; Humbert, M; Jagot, JL; Simonneau, G; Sitbon, O, 1998) |
| "Reports dealing with long-term effects of fenfluramines on brain serotonin neurons, body weight, and pulmonary function in animals and humans." | 4.79 | Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. ( McCann, UD; Ricaurte, GA; Rubin, LJ; Seiden, LS, 1997) |
| "Obesity is a chronic condition that is accompanied by a number of metabolic complications." | 3.78 | Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. ( Davis, R; Faulds, D, 1996) |
| "Appetite-suppressant drug fenfluramine is implicated in primary pulmonary hypertension (PPH) but the molecular pathways that mediate this effect are unknown." | 3.72 | Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. ( Abramowicz, MJ; Blanpain, C; Detheux, M; Knoop, C; Le Poul, E; Parma, J; Parmentier, M; Vassart, G, 2003) |
| "To test whether the clinical presentation and prognosis of fenfluramine-induced pulmonary hypertension (PH) differs from primary PH (PPH), we compared the clinical profile and outcome of 10 patients with fenfluramine-induced PH with that of 70 patients with PPH referred to our center over the same time frame and treated identically." | 3.72 | Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. ( McLaughlin, V; Rich, S; Shillington, A, 2003) |
| "This study investigated whether patients developing pulmonary arterial hypertension (PAH) after exposure to the appetite suppressants fenfluramine and dexfenfluramine have mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene, as reported in primary pulmonary hypertension." | 3.71 | BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. ( Barst, RJ; Cuervo, N; Deng, Z; Hodge, SE; Humbert, M; Knowles, JA; Moore, KJ; Morse, JH; Simonneau, G; Sitbon, O; Wolf, M, 2002) |
| "5) received fenfluramine and phentermine (fen-phen) for 7 months, and pulmonary hypertension subsequently developed." | 3.71 | Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. ( Tomita, T; Zhao, Q, 2002) |
| "In the late 1960s, an epidemic of primary pulmonary hypertension (PPH) occurred in Europe shortly after the introduction of aminorex fumarate, a potent anorexigen." | 3.70 | Aminorex, dexfenfluramine, and primary pulmonary hypertension. ( Kramer, MS; Lane, DA, 1998) |
| "Dexfenfluramine and fenfluramine greatly increase the risk of developing pulmonary hypertension (PHT)." | 3.70 | Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. ( Archer, SL; Dall'ava-Santucci, J; Dinh-Xuan, AT; Djaballah, K; Fartoukh, M; Humbert, M; Mercier, JC; Simonneau, G; Weir, KE, 1998) |
| "The anorexiant dexfenfluramine, which inhibits 5-hydroxytryptamine (5-HT) uptake, has been associated with an increase in the relative risk of developing primary pulmonary hypertension." | 3.70 | Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. ( Adnot, S; Eddahibi, S; Launay, JM; Raffestin, B; Sitbon, M, 1998) |
| "Anorectic agents, such as aminorex and fenfluramine derivatives, have been associated previously with the development of primary pulmonary hypertension." | 3.70 | Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. ( Fedullo, P; Masliah, E; Strother, J; Yi, ES, 1999) |
| "Serotoninergic appetite-suppressant drugs, fenfluramine and dexfenfluramine, were withdrawn from the market in September 1997 on account of two major cardiopulmonary complications: primary pulmonary hypertension and valvular regurgitation." | 3.70 | [Appetite suppressants and heart valve disorders]. ( Adams, C; Cohen, A, 1999) |
| "The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6." | 3.69 | Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. ( Abenhaim, L; Aubier, M; Bégaud, B; Benichou, J; Brenot, F; Higenbottam, T; Kurz, X; Moride, Y; Oakley, C; Rich, S; Simonneau, G; Wouters, E, 1996) |
| "Pulmonary hypertension was diagnosed in a 41-year-old woman after 16 months' use of fenfluramine as a treatment for obesity." | 3.69 | [Pulmonary hypertension following use of fenfluramine for obesity]. ( Maesen, BL; Snijder, RJ; Stricker, BH, 1994) |
| "Clinical observations over the past 15 years incriminated first fenfluramine and recently dexfenfluramine in the provocation of primary pulmonary hypertension." | 3.69 | High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine. ( Davis, WM; Waters, IW, 1997) |
| "The appetite suppressant aminorex fumarate is thought to have caused an epidemic of pulmonary hypertension in Europe in the 1960s." | 3.69 | Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. ( Archer, SL; Hampl, V; Huang, JM; Michelakis, E; Nelson, DP; Reeve, HL; Weir, EK, 1996) |
| "Appetite suppressants, including aminorex and fenfluramine, have been associated with pulmonary hypertension ever since the well-known outbreak of primary pulmonary hypertension in Europe after treatment with aminorex." | 3.69 | Pulmonary hypertension and dexfenfluramine. ( Cacoub, P; Dorent, R; Gandjbakhch, I; Godeau, P; Houppe, JP; Nataf, P; Piette, JC, 1995) |
| "The authors report a case of severe pulmonary hypertension after long-term dexfenfluramine treatment in a 48 year old man with no previous medical history." | 3.69 | [Severe pulmonary hypertension complicating a long treatment with dexfenfluramine]. ( Baudouy, M; Drai, E; Ferrari, E; Jourdan, J; Morand, P; Sanchez, B, 1994) |
| "There has been suggestion of a possible relationship between the intake of the appetite suppressant dexfenfluramine and the development of primary pulmonary hypertension." | 3.69 | Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. ( Delcroix, M; Leeman, M; Maggiorini, M; Naeije, R; Wauthy, P, 1995) |
| "Amphetamine-like appetite suppressants, particularly fenfluramines, have been implicated in the aetiology of primary pulmonary hypertension." | 3.69 | Appetite suppressants and primary pulmonary hypertension in the United Kingdom. ( Butt, AY; Corris, PA; Egan, JJ; Higenbottam, TW; Madden, BP; Thomas, SH; Waller, PC, 1995) |
| "Fenfluramine is a widely prescribed anorectic drug as adjuvant therapy for obesity." | 3.68 | Pulmonary hypertension and fenfluramine. ( Cheriex, EC; Pouwels, HM; Smeets, JL; Wouters, EF, 1990) |
| "Pulmonary hypertension developed in two women who had been taking fenfluramine for over eight months for weight reduction." | 3.66 | Pulmonary hypertension and fenfluramine. ( Douglas, JG; Kitchin, AH; Muir, AL; Munro, JF; Proudfoot, AT, 1981) |
| " Further studies should be conducted to determine the subsequent course of benfluorex-induced VHD and PAH, and to identify genetic, biological and clinical factors that determine individual susceptibility to developing such adverse effects." | 2.50 | Adverse effects of benfluorex on heart valves and pulmonary circulation. ( Andréjak, M; Maréchaux, S; Peltier, M; Szymanski, C; Tribouilloy, C, 2014) |
| " Receptorome screening has implicated N-deethylation of fenfluramine and serotonin 5-hydroxy-t-ryptamine 2B receptors in the adverse effects of the drug; subsequent studies corroborated this finding." | 2.43 | Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. ( Roth, BL; Setola, V, 2005) |
| "Obesity is a morbid condition with hemodynamic consequences affecting the systemic and pulmonary circulations leading to a risk of pulmonary hypertension." | 2.41 | [Pulmonary hypertension and obesity]. ( Humbert, M; Ioos, V; Parent, F; Simonneau, G; Sitbon, O; Sztrymf, B, 2002) |
| "Dexfenfluramine can cause the anorexigen-induced form of PPH that is clinically and histologically indistinguishable from PPH." | 2.40 | A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. ( Archer, SL; Johnson, G; Michelakis, ED; Nelson, DP; Reeve, HL; Weir, EK, 1998) |
| "Benfluorex is a fenfluramine derivative which has been marketed between 1976 and 2009." | 1.46 | Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report. ( Banfi, C; Baufreton, C; Bruneval, P; Ennezat, PV; Fouquet, O; Giraud, R; Rousselet, MC, 2017) |
| "Benfluorex was marketed in France until 2009, despite its similar pharmacological properties with fenfluramine and its derivatives known to be a cause of pulmonary arterial hypertension (PAH)." | 1.38 | Pulmonary hypertension associated with benfluorex exposure. ( Bergot, E; Bourdin, A; Chaumais, MC; Cottin, V; Dromer, C; Frachon, I; Habib, G; Humbert, M; Jaïs, X; Lamblin, N; Montani, D; Pison, C; Poubeau, P; Prevot, G; Reynaud-Gaubert, M; Sanchez, O; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P, 2012) |
| "Benfluorex is an amphetamine appetite suppressant derived from fenfluramine." | 1.36 | Benfluorex: increasing reports of valve disorders. ( , 2010) |
| "Schistosomiasis and chronic haemolytic anaemia have been included among the group of associated PAH." | 1.36 | [Diagnosis and classification of pulmonary hypertension]. ( Chaouat, A; Montani, D, 2010) |
| "Pulmonary hypertension was strongly associated with MR but not AR." | 1.35 | Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. ( Allen, MR; Dahl, CF; Hopkins, PN; Urie, PM, 2008) |
| "The most common finding was mild aortic regurgitation." | 1.31 | Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. ( Connolly, HM; Grogan, M; Miller, FA; Teramae, CY, 2000) |
| "Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs." | 1.30 | High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. ( Delcroix, M; Demedts, M; Kurz, X; Naeije, R; Walckiers, D, 1998) |
| "Marked obesity is an independent risk factor for multi-system morbidity." | 1.30 | [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants]. ( Goldstein, SE; Levy, Y; Shoenfeld, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (9.48) | 18.7374 |
| 1990's | 61 (52.59) | 18.2507 |
| 2000's | 30 (25.86) | 29.6817 |
| 2010's | 13 (11.21) | 24.3611 |
| 2020's | 1 (0.86) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, M | 1 |
| Daboul, J | 1 |
| Iftikhar, S | 1 |
| Burmeister, C | 1 |
| Ambati, A | 1 |
| Moukarbel, G | 1 |
| Assaly, R | 1 |
| Schoonjans, AS | 1 |
| Marchau, F | 1 |
| Paelinck, BP | 1 |
| Lagae, L | 1 |
| Gammaitoni, A | 1 |
| Pringsheim, M | 1 |
| Keane, MG | 1 |
| Ceulemans, B | 1 |
| Souza, R | 2 |
| Jardim, C | 1 |
| Humbert, M | 8 |
| Szymanski, C | 1 |
| Andréjak, M | 1 |
| Peltier, M | 1 |
| Maréchaux, S | 2 |
| Tribouilloy, C | 2 |
| Baufreton, C | 1 |
| Bruneval, P | 1 |
| Rousselet, MC | 1 |
| Ennezat, PV | 1 |
| Fouquet, O | 1 |
| Giraud, R | 1 |
| Banfi, C | 1 |
| Dahl, CF | 1 |
| Allen, MR | 1 |
| Urie, PM | 1 |
| Hopkins, PN | 1 |
| Gueffet, JP | 2 |
| Piriou, N | 1 |
| Trochu, JN | 1 |
| Montani, D | 2 |
| Chaouat, A | 1 |
| Droogmans, S | 1 |
| Cosyns, B | 1 |
| Van Camp, G | 1 |
| Le Ven, F | 1 |
| Habib, G | 2 |
| Eicher, JC | 1 |
| Blanchard-Lemoine, B | 1 |
| Rousseau, J | 1 |
| Hénon, P | 1 |
| Jobic, Y | 1 |
| Etienne, Y | 1 |
| Nau, JY | 1 |
| Surapaneni, P | 1 |
| Vinales, KL | 1 |
| Najib, MQ | 1 |
| Chaliki, HP | 1 |
| Savale, L | 1 |
| Chaumais, MC | 1 |
| Cottin, V | 1 |
| Bergot, E | 1 |
| Frachon, I | 1 |
| Prevot, G | 1 |
| Pison, C | 1 |
| Dromer, C | 1 |
| Poubeau, P | 1 |
| Lamblin, N | 1 |
| Reynaud-Gaubert, M | 1 |
| Bourdin, A | 1 |
| Sanchez, O | 1 |
| Tubert-Bitter, P | 1 |
| Jaïs, X | 2 |
| Sitbon, O | 6 |
| Simonneau, G | 9 |
| Seghatol, FF | 1 |
| Rigolin, VH | 1 |
| Deng, Z | 1 |
| Barst, RJ | 1 |
| Wolf, M | 1 |
| Cuervo, N | 1 |
| Moore, KJ | 1 |
| Hodge, SE | 1 |
| Knowles, JA | 1 |
| Morse, JH | 2 |
| Gross, SB | 2 |
| Lepor, NE | 1 |
| Rich, S | 3 |
| Shillington, A | 1 |
| McLaughlin, V | 1 |
| Blanpain, C | 1 |
| Le Poul, E | 1 |
| Parma, J | 1 |
| Knoop, C | 1 |
| Detheux, M | 1 |
| Parmentier, M | 1 |
| Vassart, G | 1 |
| Abramowicz, MJ | 1 |
| Higenbottam, T | 3 |
| Laude, L | 1 |
| Emery, C | 1 |
| Essener, M | 1 |
| Etienne, N | 1 |
| Schaerlinger, B | 1 |
| Jaffré, F | 1 |
| Maroteaux, L | 1 |
| Horton, MR | 1 |
| Tuder, RM | 1 |
| Widmar, B | 1 |
| Setola, V | 1 |
| Roth, BL | 1 |
| Leung, YY | 1 |
| Tang, KS | 1 |
| Tsang, CC | 1 |
| Chan, CK | 1 |
| Wong, KK | 1 |
| Yu, AW | 1 |
| Sztrymf, B | 2 |
| Yaïci, A | 1 |
| Le Pavec, J | 1 |
| Parent, F | 4 |
| Hervé, P | 4 |
| Soubrier, F | 1 |
| Weir, EK | 4 |
| Obreztchikova, M | 1 |
| Hong, Z | 1 |
| Douglas, JG | 2 |
| Gough, J | 1 |
| Preston, PG | 1 |
| Frazer, I | 1 |
| Haslett, C | 1 |
| Chalmers, SR | 1 |
| Munro, JF | 2 |
| Kitchin, AH | 1 |
| Muir, AL | 1 |
| Proudfoot, AT | 1 |
| Wheeley, MS | 1 |
| Doogan, DP | 1 |
| Gaul, G | 1 |
| Blazek, G | 1 |
| Deutsch, E | 1 |
| Heeger, H | 1 |
| Cacoub, P | 1 |
| Dorent, R | 1 |
| Nataf, P | 1 |
| Houppe, JP | 1 |
| Piette, JC | 1 |
| Godeau, P | 2 |
| Gandjbakhch, I | 1 |
| Maesen, BL | 1 |
| Snijder, RJ | 1 |
| Stricker, BH | 1 |
| Ferrari, E | 1 |
| Drai, E | 1 |
| Jourdan, J | 1 |
| Sanchez, B | 1 |
| Baudouy, M | 1 |
| Morand, P | 1 |
| Naeije, R | 3 |
| Wauthy, P | 1 |
| Maggiorini, M | 1 |
| Leeman, M | 1 |
| Delcroix, M | 2 |
| Brenot, F | 2 |
| Petitpretz, P | 1 |
| Duroux, P | 1 |
| Thomas, SH | 1 |
| Butt, AY | 1 |
| Corris, PA | 1 |
| Egan, JJ | 1 |
| Higenbottam, TW | 1 |
| Madden, BP | 1 |
| Waller, PC | 1 |
| De Backer, D | 1 |
| Vachiéry, JL | 1 |
| De Vuyst, P | 1 |
| Manson, JE | 1 |
| Faich, GA | 1 |
| Abenhaim, L | 2 |
| Moride, Y | 1 |
| Benichou, J | 1 |
| Kurz, X | 2 |
| Oakley, C | 1 |
| Wouters, E | 1 |
| Aubier, M | 1 |
| Bégaud, B | 1 |
| Voelkel, NF | 2 |
| Reeve, HL | 2 |
| Huang, JM | 1 |
| Michelakis, E | 1 |
| Nelson, DP | 2 |
| Hampl, V | 2 |
| Archer, SL | 3 |
| Havron, MD | 1 |
| Sztuke-Fournier, A | 1 |
| Fishman, AP | 1 |
| Clarke, WR | 1 |
| Davis, R | 1 |
| Faulds, D | 1 |
| Anchors, M | 1 |
| Deitel, M | 2 |
| Connolly, HM | 3 |
| Crary, JL | 1 |
| McGoon, MD | 2 |
| Hensrud, DD | 1 |
| Edwards, BS | 1 |
| Edwards, WD | 1 |
| Schaff, HV | 1 |
| Mark, EJ | 1 |
| Patalas, ED | 1 |
| Chang, HT | 1 |
| Evans, RJ | 1 |
| Kessler, SC | 1 |
| Curfman, GD | 1 |
| McCann, UD | 1 |
| Seiden, LS | 1 |
| Rubin, LJ | 1 |
| Ricaurte, GA | 1 |
| Graham, DJ | 1 |
| Green, L | 1 |
| Hancock, EW | 1 |
| Olschewski, H | 1 |
| Spitzer, WO | 1 |
| Hirsch, J | 1 |
| Scheen, AJ | 1 |
| Cheng, TO | 1 |
| Davis, WM | 1 |
| Waters, IW | 1 |
| Connolly, J | 1 |
| Verni, C | 1 |
| Trilling, J | 1 |
| Kelso, E | 1 |
| Shiesha, S | 1 |
| Brown-Beasley, MW | 1 |
| Kramer, MS | 1 |
| Lane, DA | 1 |
| Eddahibi, S | 1 |
| Raffestin, B | 1 |
| Launay, JM | 1 |
| Sitbon, M | 1 |
| Adnot, S | 1 |
| Hilsen, K | 1 |
| Davis, S | 1 |
| Iyer, P | 1 |
| Langleben, D | 1 |
| Shiffman, MA | 1 |
| Walckiers, D | 1 |
| Demedts, M | 1 |
| Fartoukh, M | 2 |
| Jagot, JL | 1 |
| Johnson, G | 1 |
| Michelakis, ED | 2 |
| Lin, DY | 1 |
| Psaty, BM | 1 |
| Kronmal, RA | 1 |
| Heal, DJ | 1 |
| Aspley, S | 1 |
| Prow, MR | 1 |
| Jackson, HC | 1 |
| Martin, KF | 1 |
| Cheetham, SC | 1 |
| Djaballah, K | 1 |
| Weir, KE | 1 |
| Dall'ava-Santucci, J | 1 |
| Mercier, JC | 1 |
| Dinh-Xuan, AT | 1 |
| Cherin, P | 1 |
| Tellier, P | 3 |
| Biron, CR | 1 |
| Louis, WJ | 1 |
| Strother, J | 1 |
| Fedullo, P | 1 |
| Yi, ES | 1 |
| Masliah, E | 1 |
| Rothman, RB | 3 |
| Ayestas, MA | 1 |
| Dersch, CM | 1 |
| Baumann, MH | 1 |
| Adams, C | 1 |
| Cohen, A | 1 |
| MacLean, MR | 1 |
| Rubin, L | 1 |
| Walker, AM | 1 |
| Schneeweiss, S | 1 |
| Poston, WS | 1 |
| Foreyt, JP | 1 |
| Redmon, JB | 1 |
| Raatz, SK | 1 |
| Kwong, CA | 1 |
| Swanson, JE | 1 |
| Bantle, JP | 1 |
| Teramae, CY | 1 |
| Grogan, M | 1 |
| Miller, FA | 1 |
| Widgren, S | 1 |
| Bíbová, J | 1 |
| Allen, S | 1 |
| Henderson, J | 1 |
| Goldstein, SE | 1 |
| Levy, Y | 1 |
| Shoenfeld, Y | 1 |
| Wolf, I | 1 |
| Mouallem, M | 1 |
| Farfel, Z | 1 |
| Nunes, H | 1 |
| Tomita, T | 1 |
| Zhao, Q | 1 |
| Ioos, V | 1 |
| Atanassoff, PG | 1 |
| Weiss, BM | 1 |
| Schmid, ER | 1 |
| Tornic, M | 1 |
| Roche, N | 1 |
| Labrune, S | 1 |
| Braun, JM | 1 |
| Huchon, GJ | 1 |
| Fotiadis, I | 1 |
| Apostolou, T | 1 |
| Koukoulas, A | 1 |
| Michelacakis, N | 1 |
| Kremastinos, D | 1 |
| Pouwels, HM | 1 |
| Smeets, JL | 1 |
| Cheriex, EC | 1 |
| Wouters, EF | 1 |
| McMurray, J | 2 |
| Bloomfield, P | 2 |
| Miller, HC | 2 |
| Watters, K | 1 |
| Le Ridant, A | 1 |
| Loogen, F | 1 |
| Worth, H | 1 |
| Schwan, G | 1 |
| Goeckenjan, G | 1 |
| Lösse, B | 1 |
| Horstkotte, D | 1 |
| Homann, G | 1 |
| Prime, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)[NCT01725256] | Phase 2 | 29 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to Terminated early dt to acquisition of Sponsor and change in corporate priorities) | ||
| A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension[NCT01725269] | Phase 2 | 17 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Terminated early dt acquisition of Sponsor and change in corporate priorities) | ||
| High Incidence of Adult Respiratory Distress Syndrome Associated With Amphetamine Use in the Burn Population[NCT05611385] | 49 participants (Actual) | Observational | 2019-01-01 | Completed | |||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China[NCT01417338] | 3,079 participants (Anticipated) | Observational | 2009-08-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for fenfluramine and Pulmonary Hypertension
| Article | Year |
|---|---|
Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.
Topics: Adult; Appetite Depressants; Dexfenfluramine; Epilepsies, Myoclonic; Fenfluramine; Heart Valve Disea | 2017 |
Adverse effects of benfluorex on heart valves and pulmonary circulation.
Topics: Echocardiography; Fenfluramine; Heart Valve Diseases; Heart Valves; Humans; Hypertension, Pulmonary; | 2014 |
Appetite suppressants and valvular heart disease.
Topics: Appetite Depressants; Carcinoid Heart Disease; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; | 2002 |
Anorexigen-related cardiopulmonary toxicity.
Topics: Aminorex; Appetite Depressants; Dexfenfluramine; Echocardiography; Fenfluramine; Heart Valve Disease | 2000 |
Pulmonary hypertension as a result of drug therapy.
Topics: Appetite Depressants; Dexfenfluramine; Eosinophilia-Myalgia Syndrome; Fenfluramine; Humans; Hyperten | 2004 |
[The 5-HT2B receptor: a main cardio-pulmonary target of serotonin].
Topics: Adult; Animals; Cardiomyopathy, Dilated; Cell Survival; Fenfluramine; Fetal Heart; Genes, Lethal; Ge | 2004 |
When cure is care: diagnosis and management of pulmonary arterial hypertension.
Topics: Adenosine; Algorithms; Antihypertensive Agents; Bosentan; Bronchodilator Agents; Calcium Channel Blo | 2005 |
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
Topics: Animals; Appetite Depressants; Cardiovascular Diseases; Drug Evaluation, Preclinical; Drug-Related S | 2005 |
Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.
Topics: Fatal Outcome; Female; Fenfluramine; Heart Arrest; Humans; Hypertension, Pulmonary; Hyperthyroidism; | 2006 |
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
Topics: Animals; Appetite Depressants; Drug Tolerance; Feeding Behavior; Fenfluramine; Humans; Hypertension, | 1996 |
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
Topics: Animals; Appetite Depressants; Axons; Body Weight; Brain; Brain Chemistry; Fenfluramine; Humans; Hyp | 1997 |
Selections from current literature: pharmacological treatment of obesity.
Topics: Appetite Depressants; Drug Therapy, Combination; Fenfluramine; Humans; Hypertension, Pulmonary; Obes | 1998 |
Primary pulmonary hypertension associated with the use of fenfluramine derivatives.
Topics: Adult; Appetite Depressants; Drug Therapy, Combination; Female; Fenfluramine; Follow-Up Studies; Hum | 1998 |
A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension.
Topics: Animals; Appetite Depressants; Blood Platelets; Fenfluramine; Humans; Hypertension, Pulmonary; Muscl | 1998 |
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
Topics: Animals; Biogenic Monoamines; Cyclobutanes; Dextroamphetamine; Energy Metabolism; Fenfluramine; Huma | 1998 |
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
Topics: Appetite Depressants; Blood Platelets; Drug Synergism; Fenfluramine; Forecasting; Humans; Hypertensi | 1999 |
Obesity drugs and the heart.
Topics: Appetite Depressants; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pulmonary; Phentermi | 1999 |
Scientific and legal issues in fenfluramine/dexfenfluramine litigation.
Topics: Anti-Obesity Agents; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pulm | 2000 |
Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.
Topics: Appetite Depressants; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pul | 1999 |
[Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].
Topics: Appetite Depressants; Cardiomyopathies; Drug Therapy, Combination; Fenfluramine; Heart Valve Disease | 1998 |
Anorectic drugs and pulmonary hypertension from the bedside to the bench.
Topics: Aminorex; Appetite Depressants; Dexfenfluramine; Fenfluramine; Humans; Hypertension, Pulmonary; Obes | 2001 |
Risk factors for pulmonary arterial hypertension.
Topics: Altitude; Aminorex; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second- | 2001 |
Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts.
Topics: Appetite Depressants; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pulmonary; Obesity; | 2001 |
[Pulmonary hypertension and obesity].
Topics: Aminorex; Fenfluramine; Hemodynamics; Humans; Hypertension, Pulmonary; Hypothyroidism; Hypoxia; Obes | 2002 |
3 trials available for fenfluramine and Pulmonary Hypertension
| Article | Year |
|---|---|
Long-term efficacy of fenfluramine in treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Fen | 1983 |
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
Topics: Animals; Appetite Depressants; Drug Tolerance; Feeding Behavior; Fenfluramine; Humans; Hypertension, | 1996 |
Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fem | 2000 |
90 other studies available for fenfluramine and Pulmonary Hypertension
| Article | Year |
|---|---|
Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine.
Topics: Fenfluramine; Humans; Hypertension, Pulmonary; Obesity; Phentermine; Weight Loss | 2023 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial | 2013 |
Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report.
Topics: Appetite Depressants; Fatal Outcome; Female; Fenfluramine; Heart Valve Diseases; Heart Valve Prosthe | 2017 |
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Obesity Agents; Echocardiography; Female; Fenflura | 2008 |
Benfluorex: negative data in France, but still on the market. Neuropsychiatric disorders, pulmonary hypertension and heart valve damage.
Topics: Appetite Depressants; Fenfluramine; France; Heart Valve Diseases; Humans; Hypertension, Pulmonary; N | 2009 |
Benfluorex: increasing reports of valve disorders.
Topics: Appetite Depressants; Fenfluramine; France; Heart Valve Diseases; Humans; Hypertension, Pulmonary; P | 2010 |
Valvular heart disease associated with benfluorex.
Topics: Appetite Depressants; Diuretics; Echocardiography, Doppler, Color; Female; Fenfluramine; Furosemide; | 2010 |
[Diagnosis and classification of pulmonary hypertension].
Topics: Activin Receptors, Type II; Anemia, Hemolytic; Bone Morphogenetic Protein Receptors, Type II; Cardia | 2010 |
Benfluorex: the last chapter of drug-induced valvular heart disease?
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Appetite Depressants; Europe; Fenfluramine; France; | 2011 |
Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry.
Topics: Appetite Depressants; Body Mass Index; Comorbidity; Dose-Response Relationship, Drug; Echocardiograp | 2011 |
Benfluorex: how many deaths?
Topics: Appetite Depressants; Familial Primary Pulmonary Hypertension; Fenfluramine; France; Heart Valve Dis | 2011 |
[The French are wary of their drugs].
Topics: Appetite Depressants; Body Mass Index; Cause of Death; Drugs, Generic; Fenfluramine; France; Heart V | 2011 |
Valvular heart disease with the use of fenfluramine-phentermine.
Topics: Anti-Obesity Agents; Drug Combinations; Echocardiography, Doppler, Color; Female; Fenfluramine; Gast | 2011 |
Pulmonary hypertension associated with benfluorex exposure.
Topics: Adult; Aged; Appetite Depressants; Familial Primary Pulmonary Hypertension; Female; Fenfluramine; Hu | 2012 |
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Bone Morphogenetic Protein Receptors, Type II; Dexfen | 2002 |
Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension.
Topics: Adult; Chi-Square Distribution; Female; Fenfluramine; Hemodynamics; Humans; Hypertension, Pulmonary; | 2003 |
Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.
Topics: Animals; Appetite Depressants; Calcium; Case-Control Studies; Cell Membrane; CHO Cells; COS Cells; C | 2003 |
Primary pulmonary arterial hypertension presenting as diffuse micronodules on CT.
Topics: Adult; Appetite Depressants; Asthma; Drug Combinations; Female; Fenfluramine; Humans; Hypertension, | 2004 |
Appetite suppressants and pulmonary hypertension: a long-term risk.
Topics: Appetite Depressants; Dexfenfluramine; Fenfluramine; France; Humans; Hypertension, Pulmonary; Risk F | 2006 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
Topics: Adult; Age Distribution; Analysis of Variance; Appetite Depressants; Confidence Intervals; Female; F | 2008 |
Fenfluramine: riddle or Rosetta stone?
Topics: Animals; Appetite Depressants; Disease Models, Animal; Dose-Response Relationship, Drug; Fenfluramin | 2008 |
Pulmonary hypertension and fenfluramine.
Topics: Adult; Electrocardiography; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; Obes | 1981 |
Pulmonary hypertension and fenfluramine.
Topics: Female; Fenfluramine; Humans; Hypertension, Pulmonary | 1981 |
Pulmonary hypertension and fenfluramine.
Topics: Fenfluramine; Humans; Hypertension, Pulmonary; Serotonin | 1982 |
[A case of chronic pulmonary hypertension after fenfluramine intake].
Topics: Chronic Disease; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; Nifedipine; Obe | 1982 |
Pulmonary hypertension and dexfenfluramine.
Topics: Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged | 1995 |
[Pulmonary hypertension following use of fenfluramine for obesity].
Topics: Adult; Female; Fenfluramine; Heart Function Tests; Humans; Hypertension, Pulmonary; Obesity; Pulmona | 1994 |
[Severe pulmonary hypertension complicating a long treatment with dexfenfluramine].
Topics: Dose-Response Relationship, Drug; Fatal Outcome; Fenfluramine; Humans; Hypertension, Pulmonary; Male | 1994 |
Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs.
Topics: Animals; Dogs; Fenfluramine; Hypertension, Pulmonary; Hypoxia; Ketanserin; Pulmonary Artery; Pulmona | 1995 |
Primary pulmonary hypertension and fenfluramine use.
Topics: Adult; Cardiac Catheterization; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged; | 1993 |
Appetite suppressants and primary pulmonary hypertension in the United Kingdom.
Topics: Adult; Appetite Depressants; Diethylpropion; Female; Fenfluramine; Heart-Lung Transplantation; Human | 1995 |
High-altitude pulmonary edema with primary pulmonary hypertension.
Topics: Adult; Altitude Sickness; Appetite Depressants; Female; Fenfluramine; Humans; Hypertension, Pulmonar | 1996 |
Pharmacotherapy for obesity -- do the benefits outweigh the risks?
Topics: Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity | 1996 |
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Belgium; Case-Control Studies; Female; Fenfluramine; | 1996 |
Drug-induced pulmonary hypertension: must history repeat itself?
Topics: Appetite Depressants; Drug Approval; Fenfluramine; Humans; Hypertension, Pulmonary; Selective Seroto | 1996 |
Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.
Topics: Aminorex; Animals; Appetite Depressants; Enzyme Inhibitors; Fenfluramine; Hypertension, Pulmonary; M | 1996 |
Diet drugs and pulmonary hypertension.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Clinical Trials as Topic; Female; Fenfluramine; Human | 1996 |
Primary pulmonary hypertension and long-term use of appetite suppressants.
Topics: Adult; Appetite Depressants; Body Mass Index; Female; Fenfluramine; Humans; Hypertension, Pulmonary; | 1997 |
Appetite-suppressant drugs and primary pulmonary hypertension.
Topics: Aminorex; Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity | 1997 |
Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned?
Topics: Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity | 1997 |
Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Hypertension, Pulmonary; Obesity; Selective | 1997 |
Debate over dexfenfluramine.
Topics: Appetite Depressants; Body Mass Index; Fenfluramine; Humans; Hypertension, Pulmonary; Logistic Model | 1997 |
Valvular heart disease associated with fenfluramine-phentermine.
Topics: Adult; Aortic Valve Insufficiency; Appetite Depressants; Drug Combinations; Female; Fenfluramine; He | 1997 |
Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
Topics: Adult; Appetite Depressants; Drug Combinations; Fatal Outcome; Female; Fenfluramine; Humans; Hyperte | 1997 |
Diet pills redux.
Topics: Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; Hyperte | 1997 |
Further cases of valvular heart disease associated with fenfluramine-phentermine.
Topics: Adult; Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; | 1997 |
Obesity and an abnormal ECG.
Topics: Adult; Appetite Depressants; Drug Combinations; Electrocardiography; Female; Fenfluramine; Humans; H | 1997 |
[Appetite depressant drugs and the risk of primary pulmonary hypertension].
Topics: Adult; Appetite Depressants; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Long-Term Care; | 1997 |
Valvular heart disease associated with fenfluramine-phentermine.
Topics: Appetite Depressants; Bias; Drug and Narcotic Control; Drug Combinations; Female; Fenfluramine; Hear | 1997 |
The treatment of obesity with drugs.
Topics: Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; Hyperte | 1998 |
[Drug-clinics. The hue and cry over central appetite suppressants!].
Topics: Adrenergic Agents; Adult; Amphetamines; Appetite; Appetite Depressants; Female; Fenfluramine; Heart | 1997 |
Mitral valve disease associated with use of anorexigenic medications.
Topics: Appetite Depressants; Drug Combinations; Female; Fenfluramine; Heart Valve Diseases; Humans; Hyperte | 1998 |
High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine.
Topics: Altitude; Animals; Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary; Lung; Pulmon | 1997 |
After fen-phen/Redux: cardiac and pulmonary sequelae implications for patient assessment.
Topics: Adult; Appetite Depressants; Drug Combinations; Emergency Nursing; Female; Fenfluramine; Humans; Hyp | 1998 |
Aminorex, dexfenfluramine, and primary pulmonary hypertension.
Topics: Adult; Aminorex; Appetite Depressants; Europe; Female; Fenfluramine; Humans; Hypertension, Pulmonary | 1998 |
Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Appetite Depressants; B | 1998 |
Fen-phen's message to dentists.
Topics: Appetite Depressants; Dental Care for Chronically Ill; Drug Combinations; Fenfluramine; Heart Valve | 1998 |
Relearning the lessons of history: anorexigens and pulmonary hypertension.
Topics: Aminorex; Appetite Depressants; Drug Approval; Fenfluramine; Humans; Hypertension, Pulmonary | 1998 |
Anesthesia risks in patients who have had antiobesity medication.
Topics: Anesthesia, General; Appetite Depressants; Contraindications; Fenfluramine; Heart Valve Diseases; Hu | 1998 |
High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
Topics: Adult; Appetite Depressants; Belgium; Case-Control Studies; Female; Fenfluramine; Humans; Hypertensi | 1998 |
Appetite-suppressant drugs and the risk of primary pulmonary hypertension?
Topics: Appetite Depressants; Body Mass Index; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Incide | 1997 |
Assessing the sensitivity of regression results to unmeasured confounders in observational studies.
Topics: Appetite Depressants; Biometry; Cardiac Catheterization; Case-Control Studies; Cohort Studies; Fenfl | 1998 |
Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
Topics: Adult; Aged; Angina Pectoris; Appetite Depressants; Case-Control Studies; Dexfenfluramine; Disease S | 1998 |
[Pulmonary hypertension and heart valve diseases induced by fenfluramine? Hypothesis or certitude? Myth or reality?].
Topics: Animals; Aortic Valve Insufficiency; Appetite Depressants; Dexfenfluramine; Female; Fenfluramine; He | 1998 |
Former Fen-Phen users may need prophylactic antibiotic before treatment.
Topics: Antibiotic Prophylaxis; Appetite Depressants; Dental Care for Chronically Ill; Drug Combinations; En | 1998 |
Primary pulmonary hypertension and anorectic drugs.
Topics: Anti-Asthmatic Agents; Appetite Depressants; Diuretics; Drug Combinations; Fenfluramine; Humans; Hyp | 1999 |
Severe heart valve disease on appetite suppressants.
Topics: Adult; Appetite Depressants; Case-Control Studies; Diethylpropion; Drug Approval; Drug Combinations; | 1998 |
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension.
Topics: Adult; Appetite Depressants; Fatal Outcome; Female; Fenfluramine; Humans; Hypertension, Pulmonary; P | 1999 |
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.
Topics: Aminorex; Animals; Appetite Depressants; Brain; Carrier Proteins; Chlorphentermine; Dopamine; Fenflu | 1999 |
[Appetite suppressants and heart valve disorders].
Topics: Adult; Aged; Aortic Valve Insufficiency; Appetite Depressants; Dexfenfluramine; Female; Fenfluramine | 1999 |
Aminorex to Fen/Phen: an epidemic foretold.
Topics: Aminorex; Appetite Depressants; Drug Therapy, Combination; Fenfluramine; Heart Valve Diseases; Human | 1999 |
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
Topics: Adult; Aged; Amphetamines; Appetite Depressants; Canada; Causality; Cross-Sectional Studies; Female; | 2000 |
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
Topics: Adult; Aged; Amphetamines; Appetite Depressants; Canada; Causality; Cross-Sectional Studies; Female; | 2000 |
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
Topics: Adult; Aged; Amphetamines; Appetite Depressants; Canada; Causality; Cross-Sectional Studies; Female; | 2000 |
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
Topics: Adult; Aged; Amphetamines; Appetite Depressants; Canada; Causality; Cross-Sectional Studies; Female; | 2000 |
Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Female; Fenfluramine; Heart Valve Diseases; Humans | 2000 |
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramin.
Topics: Appetite Depressants; Autopsy; Fatal Outcome; Female; Fenfluramine; Humans; Hypertension, Pulmonary; | 2000 |
[Anorectics and pulmonary hypertension].
Topics: Appetite Depressants; Dexfenfluramine; Fenfluramine; Humans; Hypertension, Pulmonary; Risk Factors; | 2000 |
Fen-phen manufacturers, not physicians, are liable.
Topics: Appetite Depressants; Drug Combinations; Drug Industry; Fenfluramine; Heart Valve Diseases; Humans; | 2000 |
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
Topics: Aged; Appetite Depressants; Drug Therapy, Combination; Female; Fenfluramine; Heart Valve Diseases; H | 1998 |
The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use.
Topics: Adult; Age Factors; Appetite Depressants; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Mal | 2000 |
Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine.
Topics: Adult; Appetite Depressants; Drug Combinations; Female; Fenfluramine; Humans; Hypertension, Pulmonar | 2002 |
Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension.
Topics: Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein Receptors, Type II; Bone Morphogen | 2002 |
Pulmonary hypertension and dexfenfluramine.
Topics: Adult; Female; Fenfluramine; Humans; Hypertension, Pulmonary; Pregnancy; Pregnancy Complications, Ca | 1992 |
Pulmonary hypertension and dexfenfluramine.
Topics: Adult; Female; Fenfluramine; Humans; Hypertension, Pulmonary | 1992 |
Fenfluramine--induced irreversible pulmonary hypertension.
Topics: Female; Fenfluramine; Humans; Hypertension, Pulmonary | 1991 |
Pulmonary hypertension and fenfluramine.
Topics: Female; Fenfluramine; Heart Failure; Humans; Hypertension, Pulmonary; Middle Aged; Obesity | 1990 |
Irreversible pulmonary hypertension after treatment with fenfluramine.
Topics: Female; Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged | 1986 |
Irreversible pulmonary hypertension after treatment with fenfluramine.
Topics: Fenfluramine; Humans; Hypertension, Pulmonary; Middle Aged | 1986 |
Irreversible pulmonary hypertension after treatment with fenfluramine.
Topics: Female; Fenfluramine; Humans; Hypertension, Pulmonary | 1986 |
Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake.
Topics: Adolescent; Adult; Aged; Aminorex; Appetite Depressants; Child; Electrocardiography; Female; Fenflur | 1985 |
[Pulmonary hypertension following use of appetite depressants?].
Topics: Appetite Depressants; Fenfluramine; Humans; Hypertension, Pulmonary | 1974 |
Dangers of certain appetite suppressants.
Topics: Appetite Depressants; Fenfluramine; Fluorine; Humans; Hypertension, Pulmonary; Phenethylamines | 1969 |